Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.
复制标题
肾功能不良患者血浆中二苯乙内酰脲和去甲基丙咪嗪的蛋白结合。
DOI：
--
复制
发表时间：
1971
影响因子：
158.5
通讯作者：
F. Sjöqvist
中科院分区：
文献类型：
--
作者：
M. Reidenberg;I. Odar‐Cederlöf;C. Bahr;O. Borgå;F. Sjöqvist
摘要采用超滤技术测定了偶氮血症和尿毒症患者血浆中二苯肼（DPH）和去甲基咪嗪（DMI）的蛋白结合。尿毒症血浆中DPH结合降低。结合损伤与患者氮血症程度和身体残疾程度呈强相关（p < 0.001），与血清蛋白浓度呈弱相关（p < 0.05）。DMI结合基本正常。正常血浆和尿毒症血浆在自来水或血液透析溶液中透析均未改变DPH结合。偶氮患者血浆蛋白对DPH的结合似乎减少了，可能是由于结合蛋白的变化。当测量蛋白结合药物的总血浆浓度和用于建立或修改药物给药方案的值时，应考虑病理状态改变药物结合的可能性。
Abstract The protein binding of diphenylhydantoin (DPH) and desmethylimipramine (DMI) was measured in plasma from azotemic and uremic patients by an Ultrafiltration technic. DPH binding was decreased in uremic plasma. The impairment of binding was strongly correlated (p less than 0.001) to the degree of azotemia and degree of physical disability of the patients but weakly correlated (p less than 0.05) to their concentrations of serum proteins. DMI binding was almost normal. Dialysis of normal and uremic plasma in tap water or hemodialysis solution did not alter the DPH binding. The binding of DPH by plasma proteins from azotemic patients appears to be decreased, probably owing to a change in the binding proteins. The possibility of alteration of drug binding by pathologic states should be considered when total plasma concentrations of protein-bound drugs are measured and the values used to establish or modify drug-dosage regimens.